GleamWall
中文EN

SEPN Septerna, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1984086 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY336.7%
TTM net income YoY-0.3%
TTM EPS YoY-109.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-76.2%
Net margin-61.3%
FCF margin-80.6%
EBITDA margin-74.6%

Returns

ROE-14.4%
ROA-9.6%
ROIC (approx.)-35.2%
Asset turnover0.16x

Leverage & solvency

Liabilities / assets30.9%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.30x
Accruals ratio2.9%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$18.88M$26.75M$26.52M$24.12M$21.50M$119,000$219,000$212,000
R&D expense$36.56M$35.13M$29.54M$31.86M$24.26M$22.19M$19.27M$19.32M
SG&A expense$9.55M$8.45M$10.29M$8.28M$7.12M$6.91M$6.86M$5.61M
Operating income-$27.23M-$16.84M-$13.30M-$16.02M$2.61M-$28.98M-$25.91M-$24.72M
Pretax income-$21.97M-$12.06M-$8.30M-$10.73M$8.17M-$24.84M-$21.48M-$20.83M
Income tax$4.62M$973,000$337,000$12,000$0$0$0-$160,000
Net income-$26.59M-$13.03M-$8.64M-$10.74M$8.17M-$24.84M-$21.48M-$20.67M
EBITDA-$26.83M-$16.44M-$12.90M-$15.62M$3.01M-$28.58M-$25.51M-$24.32M
EPS (basic)-0.57-0.29-0.19—0.18-0.56-0.49—
EPS (diluted)-0.57-0.29-0.19—0.18-0.56-0.49—
Weighted avg. shares (diluted)46.91M45.04M44.76M—45.60M44.17M43.94M—
Balance sheet
Cash & equivalents$167.12M$84.66M$71.61M$120.72M$319.99M$189.31M$210.04M$238.20M
Short-term investments$311.48M$287.66M$275.80M$270.37M$154.36M$137.25M$125.96M$112.73M
Receivables$18.88M$12.16M$10.84M$10.36M$8.64M$151,000$250,000$171,000
Current assets$507.35M$396.15M$368.06M$410.96M$491.68M$334.14M$342.47M$356.82M
PP&E, net$3.83M$3.90M$4.33M$4.43M$4.32M$4.69M$5.04M$5.09M
Total assets$619.40M$566.74M$569.69M$596.19M$606.65M$415.23M$434.02M$456.55M
Current liabilities$104.86M$79.32M$78.17M$86.93M$75.28M$15.13M$10.64M$12.85M
Total liabilities$191.47M$180.02M$191.23M$214.26M$217.92M$37.67M$33.75M$36.51M
Shareholders' equity$427.93M$386.72M$378.46M$381.93M$388.73M$377.56M$400.27M$420.05M
Shares outstanding47.41M45.67M44.92M44.81M44.64M44.57M44.45M44.42M
Cash flow statement
Operating cash flow-$13.77M-$22.18M-$25.63M-$14.99M$168.81M-$20.29M-$23.34M-$20.96M
Capital expenditure$127,000$0$832,000$65,000$13,000$58,000$382,000$612,000
Free cash flow-$13.89M-$22.18M-$26.46M-$15.05M$168.79M-$20.34M-$23.73M-$21.57M
Investing cash flow$33.48M$18.41M-$23.82M-$185.30M-$38.39M-$786,000-$4.87M-$133.24M
Financing cash flow$62.75M$16.82M$333,000$1.02M$263,000$339,000$66,000$304.15M
Depreciation & amortization$400,000$400,000$400,000$400,000$400,000$400,000$400,000$400,000
Stock-based compensation$5.92M$5.07M$6.01M$2.66M$2.53M$1.81M$1.48M$1.26M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.